Cingulate Inc.(CING), a biopharmaceutical company, Tuesday reported positive results from the Phase 3 pediatric study of its lead drug candidate CTx-1301 for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).
The primary efficacy endpoint of the study was change in total score on the ADHD-RS-5 rating scale, a scale which measures aspects of ADHD in pediatrics. In the study, CTx-1301 showed statistically significant improvements in ADHD symptoms across all doses.
The company plans to submit a new drug application for CTx-1301 this summer.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.